Sun has already tied up acquisition financing in the form of bridge loans from at least three global banks — one each from Wall Street, Europe and Japan — to the tune of $10-14 billion to show its commitment to the board of Organon.The due diligence process will start shortly, following which a binding bid will be made. But being a listed company, typically these dilligences are much shorter in nature. ET was the first to report January 19 on Sun making a play for Organon. The company told the exchanges th ...

MONTREAL, June 17, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a pan-American (ex-US) specialty pharmaceutical company, announced today that it has completed the acquisition of the Paladin business, under the terms of the definitive Asset Purchase Agreement (“APA”) entered with Paladin Pharma Inc., an Endo, Inc. operating company, as announced in March 2025. On the closing date, Knight paid approximately $107 million in cash including $22.3 million for the payment of inventory. ...